Metallo-beta-lactamases (MBLs) catalyze the hydrolysis of beta-lactams including penicillins, cephalosporins and carbapenems. Starting from benzohydroxamic acid (1) structure-activity studies led to the identification of selective inhibitors of the FEZ-1 MBL, e.g., 2,5-substituted benzophenone hydroxamic acid 17 has a K-i of 6.1 +/- 0.71 mu M against the FEZ-1 MBL but does not significantly inhibit the IMP-1, Bell, CphA or L1 MBLs. (c) 2006 Elsevier Ltd. All rights reserved.
Metallo-beta-lactamases (MBLs) catalyze the hydrolysis of beta-lactams including penicillins, cephalosporins and carbapenems. Starting from benzohydroxamic acid (1) structure-activity studies led to the identification of selective inhibitors of the FEZ-1 MBL, e.g., 2,5-substituted benzophenone hydroxamic acid 17 has a K-i of 6.1 +/- 0.71 mu M against the FEZ-1 MBL but does not significantly inhibit the IMP-1, Bell, CphA or L1 MBLs. (c) 2006 Elsevier Ltd. All rights reserved.
Isophthalic Acid-Based HDAC Inhibitors as Potent Inhibitors of HDAC8 from<i>Schistosoma mansoni</i>
作者:Katharina Stenzel、Alokta Chakrabarti、Jelena Melesina、Finn K. Hansen、Julien Lancelot、Simon Herkenhöhner、Beate Lungerich、Martin Marek、Christophe Romier、Raymond. J. Pierce、Wolfgang Sippl、Manfred Jung、Thomas Kurz
DOI:10.1002/ardp.201700096
日期:2017.8
Schistosoma mansoni histone deacetylase 8 (SmHDAC8) has been recently identified as a new potential target for the treatment of schistosomiasis. A series of newly designed and synthesized alkoxyamide‐based and hydrazide‐based HDACinhibitors were tested for inhibitory activity against SmHDAC8 and human HDACs 1, 6, and 8. The front runner compounds showed submicromolar activity against SmHDAC8 and modest